MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,BA190	SA00059807	47	F	SA00059807
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00059807	**Account Information**			**Report Notes**
Collected 07/10/2013 11:16	C7028846-DLMP Rochester SDSC 2 - Client Support Rochester, MN 55901			
Printed 10/21/2013 13:01				

Test	Flag	Results	Unit	Reference Value	Perform Site*
BCR/ABL, p190, Quant, Monitor					
RECEIVED: 07/10/2013 11:27 **REPORTED:** 07/10/2013 13:11					
Specimen Type		Peripheral blood			MCR
Final Diagnosis:					MCR

Peripheral blood, BCR/ABL mRNA level analysis (p190 fusion form):

Negative. No BCR/ABL p190 mRNA transcripts were detected (%bcr/abl(p190):abl=0). The detection limit for this sample was 0.0005%.

Signing Pathologist: Melissa Tricker-Klar
Method summary-BCR/ABL, p190 fusion: BCR/ABL p190 mRNA transcript level was evaluated using quantitative, reverse transcription PCR. The assay detects the most common fusion form (e1/a2), but does not detect other fusions, including the p210, which is the most common form found in chronic myelogenous leukemia. This assay should only be ordered for monitoring patients with a previously identified p190 fusion form. Test #89006(BCR/ABL, mRNA detection, RT-PCR, Quantitative, Diagnostic) should be ordered if the test is being performed in a diagnostic setting and test #89007(BCR/ABL, p210, mRNA detection, RT-PCR, Quantitative, Monitoring CML) should be ordered if this patient is being monitored for a known p210 fusion form. See the Mayo Medical Laboratories Interpretive Handbook for method details. Please contact the Mayo Molecular Hematopathology Laboratory at 507-266-0489 with questions or if additional testing is required.

Typical clinical samples have detection limits ranging from 0.01% to 0.0001% bcr/abl:abl. Most patients at diagnosis have a bcr/abl:abl result in the range of 20% to 100%.

The reproducibility of this assay is such that results within 0.5 log should be considered equivalent. Trends in the level of BCR/ABL mRNA should be followed and clinically significant changes verified with a subsequent specimen.
Laboratory developed test.

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:

* Report times for Mayo performed tests are CST/CDT